Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial.
Martin Reck
Consultant or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Pfizer; Roche
Honoraria - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Pfizer; Roche
Rolf Kaiser
Employment or Leadership Position - Boehringer Ingelheim
Anders Mellemgaard
No relevant relationships to disclose
Jean Yves Douillard
Consultant or Advisory Role - Boehringer Ingelheim
Sergey Orlov
No relevant relationships to disclose
Maciej Jerzy Krzakowski
No relevant relationships to disclose
Joachim Von Pawel
Consultant or Advisory Role - Boehringer Ingelheim
Maya Gottfried
No relevant relationships to disclose
Igor Bondarenko
No relevant relationships to disclose
Meilin Liao
No relevant relationships to disclose
Jose Barrueco
Employment or Leadership Position - Boehringer Ingelheim
Birgit Gaschler-Markefski
Employment or Leadership Position - Boehringer Ingelheim
Silvia Novello
No relevant relationships to disclose